Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma
Table 2
Clinical and pathological features of T1 lung adenocarcinoma patients stratified by carcinoembryonic antigen (CEA) levels. Where appropriate, data are n (%).
Characteristics
CEA < 2.12 IU/mL ()
CEA ≥ 2.12 IU/mL ()
EGFR mutated
EGFR wild type
EGFR mutated
EGFR wild type
Age, mean y (range)
58.4 ± 10.2 (26–83)
52.9 ± 10.5 (26–83)
<0.001a
63.7 ± 8.3 (38–84)
59.8 ± 8.6 (38–84)
0.002a
Sex
Male
37 (16.3)
190 (83.7)
0.260b
55 (49.1)
57 (50.9)
0.143b
Female
96 (63.6)
55 (36.4)
32 (38.6)
51 (61.4)
Smoking
Nonsmoker
115 (35.0)
214 (65.0)
0.873b
69 (49.6)
70 (50.4)
0.038b
Current/former
18 (36.7)
31 (63.3)
18 (32.1)
38 (67.9)
Type of surgery
Lobectomy
89 (36.3)
156 (63.7)
0.574b
67 (45.6)
80 (54.4)
0.738b
Limited
44 (33.1)
89 (66.9)
20 (41.7)
28 (58.3)
Tumour size
pT1a
58 (23.9)
185 (76.1)
<0.001b
18 (29.0)
44 (80.0)
0.010b
pT1b
60 (53.6)
52 (46.4)
43 (50.6)
42 (49.4)
pT1c
15 (65.2)
8 (34.8)
26 (54.2)
22 (45.8)
Histology
AIS
29 (21.5)
106 (78.5)
<0.001b
5 (14.3)
30 (85.7)
<0.001b
MIA
35 (28.2)
89 (71.8)
22 (51.2)
21 (48.8)
IAC
69 (58.0)
50 (42.0)
60 (51.3)
57 (48.7)
IAC subtype ()
Lepidic
20 (60.6)
13 (39.4)
0.344c
10 (50.0)
10 (50.0)
0.123c
Acinar
19 (41.3)
27 (58.7)
21 (56.8)
16 (43.2)
Papillary
30 (76.9)
9 (23.1)
27 (56.3)
21 (43.7)
Solid
2 (22.2)
7 (77.8)
Mucinous variant
0
1 (100.0)
0
3 (100.0)
Pleural invasion
No
124 (34.3)
238 (65.7)
0.105b
71 (42.8)
95 (57.2)
0.231b
Yes
9 (56.3)
7 (43.7)
16 (55.2)
13 (44.8)
Lymph nodes
pN0
130 (34.8)
244 (65.2)
0.127c
74 (43.0)
98 (57.0)
0.267b
pN1 or 2
3 (75.0)
1 (25.0)
13 (56.5)
10 (43.5)
Pathological stage
0
29 (21.5)
106 (78.5)
<0.001c
5 (14.3)
30 (85.7)
0.001c
IA
93 (41.5)
131 (58.5)
56 (48.7)
59 (51.3)
IB
8 (53.3)
7 (46.7)
13 (59.1)
9 (40.9)
IIA, IIB, IIIA
3 (75.0)
1 (25.0)
13 (56.5)
10 (43.5)
by at-test, bPearson’s chi-squared test, and cFisher’s exact test.
